Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 09/12/2025 GMT			5-day change	1st Jan Change
12.41 ^USD	-17.54%		-35.26%	-45.51%

12-05	Top Premarket Decliners	MT
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI

Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Published on 11/06/2025 at 09:31 pm GMT

S&P Capital IQ

Quoin Pharmaceuticals, Ltd.

-17.54%

Quoin Pharmaceuticals, Ltd. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported net loss was USD 3.95 million compared to USD 2.35 million a year ago. Basic loss per share from continuing operations was USD 6.72 compared to USD 16.45 a year ago. Diluted loss per share from continuing operations was USD 6.72 compared to USD 16.45 a year ago.
For the nine months, net loss was USD 11.46 million compared to USD 6.65 million a year ago. Basic loss per share from continuing operations was USD 19.6 compared to USD 57.05 a year ago. Diluted loss per share from continuing operations was USD 19.6 compared to USD 57.05 a year ago.

Latest news about Quoin Pharmaceuticals, Ltd.

12-05	Top Premarket Decliners	MT
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI
11-06	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-28	Quoin Pharmaceuticals Ltd. Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 Month 'Whole Body' Data Update from Ongoing Study	CI
10-22	Quoin Pharmaceuticals, Ltd. announced that it has received $16.450005 million in funding from a group of investors	CI
10-21	Quoin Pharmaceuticals announces U.S. FDA grants orphan drug designation for QRX003 in Netherton Syndrome	RE
10-13	Top Premarket Decliners	MT
10-10	Quoin Pharmaceuticals, Ltd. announced that it expects to receive $16.450005 million in funding	CI
10-10	Top Midday Gainers	MT
10-10	Quoin Pharmaceuticals Shares Jump After Announcing $104.5 Million Private Placement	MT
08-18	Quoin Pharmaceuticals Ltd. Appoints Sally Lawlor as Chief Financial Officer, Effective August 18, 2025	CI
08-18	Quoin Pharmaceuticals Names Sally Lawlor as Finance Chief	MT
08-07	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
07-08	Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	RE
07-08	Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn	CI
06-26	Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin Diseases	CI
06-24	Quoin Pharmaceuticals Ltd. Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	CI
06-24	Certain Warrants of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	CI
06-24	Certain Options of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	CI
06-24	Certain American Depositary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	CI
06-24	Certain Ordinary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	CI
05-22	Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	CI
05-22	Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	RE
05-22	Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	MT
05-14	Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing	MT

Chart Quoin Pharmaceuticals, Ltd.

Duration

Period

QNRX: Dynamic Chart

Company Profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-11 - Q4 2025 Earnings Release (Projected)

More about the company